SecBot SecBot
Institutional Cluster

ANIP

ANI PHARMACEUTICALS INC
MIXED
Impact 3/10
Horizonweeks Processed12d 22h ago
Institutional cluster: 4 buyers, 6 sellers (mixed)
Actionable Insight ◆ Mixed

The selling is concentrated among larger holders while buying comes from small advisors, suggesting a rotation rather than a uniform thesis. Monitor upcoming 13F filings for Q4 to see if the selling trend continues or reverses, especially in light of the Egetis acquisition progress.

DirectionMixed
Confidencemedium
Horizonweeks

Drugs in focus

ANIP drug pipeline →

Cortrophin Gel

▲ Bullish Named in this fund cluster
Impact
Phase
Approved
Time to market
Already approved and commercially available since January 2022.
Next catalyst
None dated

What to watchCortrophin Gel is already approved and commercialized with no pending regulatory binary. The key near-term catalysts are commercial execution metrics: Q4 2026 Cortrophin revenue (expected early Feb 2027) will show whether the specialty pharmacy capacity constraints that slowed Q3 conversion have resolved, and whether the gout sales force expansion is gaining traction. The Egetis/EMCITATE acquisition acceptance period (Nov 20-Dec 18, 2026) is a separate corporate event that could affect ANIP's balance sheet and rare disease strategy.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$67.79
T+0 close · Nov 9, 2026 · via day close
Latest settled
+4.57%
T+5 · $70.89
Vs SPY
+6.27%
α at T+5
Next horizon
T+20
in 16d
  1. T+0 · Nov 9 $67.79entry
  2. T+1 · 12d ago +5.10%α +5.47% · $71.25
  3. T+5 · 6d ago +4.57%α +6.27% · $70.89
  4. T+9 · todayOpen
  5. T+20 · in 16d Pending
  6. T+60 · in 3mo Pending

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Institutional 13F cluster for ANIP in Q3 2026 shows mixed conviction: 4 small asset managers added positions (net +$570K) while 6 larger holders trimmed a combined $19.4M, led by Bank of Montreal's $13M reduction. The cluster follows a strong Q3 earnings beat and raised guidance, but the selling by larger institutions suggests profit-taking or caution on the pending Egetis acquisition.

Key Financial Metrics

Direction
distributing
Buy Value
$931.0K
Sell Value
$19.4M
Net Flow
-$18.8M

Institutional Positions

Net institutional flow: -$18.8M

▲ Buyers (4)

InstitutionActionChangePosition ValueValue Δ
Creative PlanningDOUBLED+240.9%$786.0K$523.0K
Pnc Financial Services GroupADD+71.9%$134.0K$45.0K

▼ Sellers (6)

InstitutionActionChangePrev ValueValue Δ
Bank Of Montreal /CanTRIM-65.9%$18.6M-$13.0M
AmundiTRIM-73%$2.6M-$2.0M
Great Lakes AdvisorsTRIM-27.7%$5.1M-$1.9M
Seb Asset Management AbTRIM-27.3%$4.7M-$1.7M
Artemis Investment ManagementTRIM-27.7%$2.3M-$852.0K

Key Facts

  • 4 buyers added $570K in net new positions; 6 sellers reduced by $19.4M
  • Bank of Montreal trimmed 65.9% of its stake, selling $13M worth
  • Amundi cut 73% of its position, selling $2.0M
  • Creative Planning doubled its stake (+240.9%), adding $523K
  • All participants are asset managers; no activist or hedge fund involvement
  • Cluster data is 45+ days stale; positions reflect Q3 2026 quarter-end

Financial Impact

Net institutional selling of $18.8M (buyers added $570K, sellers removed $19.4M)

institutional ownershipfloat

Risk Factors

  • 13F data is stale (45-day lag); positions may have been unwound or added to since quarter-end
  • No insider buying corroborates the institutional cluster; insider activity shows 3 sells in the prior 30 days
  • Pending $560M Egetis acquisition introduces execution and financing risk
  • Cortrophin Gel revenue conversion slower than expected due to specialty pharmacy capacity

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
80% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 institutional 13F filing from SEC EDGAR.

DocumentAccession Number
INST-CLUSTER Data (Synthetic)inst-cluster-ANIP-2026-Q3

Track record

34 reports on ANIP

Performance horizon

4 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +8.88% at T+60 after the Apr 8, 2026 report. 8 of 12 went positive at some point.

Filters
  1. Nov 18, 20263d ago Insider Cluster Neutral 2/10 Entry $69.13 settles Dec 18
  2. Nov 16, 20265d ago 144 Neutral 2/10 Entry $69.99 settles Dec 16
  3. Nov 16, 20266d ago 8-K Neutral 3/10 Entry $70.89 settles Dec 15
  4. Nov 9, 202612d ago Institutional Cluster Mixed 3/10 Viewing Entry $67.79 settles Dec 8
  5. Nov 5, 202616d ago 8-K Neutral 5/10 Entry $67.41 settles Dec 7
  6. Nov 5, 202617d ago 8-K Bullish 6/10 No price data
  7. Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 settles Dec 4
  8. Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 settles Dec 4
  9. Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 settles Dec 4
  10. Oct 29, 202623d ago 144 Neutral 2/10 Entry $72.00 settles Nov 30
Showing 10 of 34

US Market Status

Market Closed · Opens Mon (25h 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026